[
  {
    "ts": null,
    "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2025 Update",
    "summary": "GMOâs 13F portfolio grew to $33.23B in Q2 2025, with Microsoft, Meta, Alphabet, Oracle, and Apple as top holdings. Read more about the portfolio here.",
    "url": "https://finnhub.io/api/news?id=1752da494c03f4d1c83d55ee99d4a662014fa49c4d61c67a181e3e504c898d52",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755726539,
      "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2025 Update",
      "id": 136449150,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "GMOâs 13F portfolio grew to $33.23B in Q2 2025, with Microsoft, Meta, Alphabet, Oracle, and Apple as top holdings. Read more about the portfolio here.",
      "url": "https://finnhub.io/api/news?id=1752da494c03f4d1c83d55ee99d4a662014fa49c4d61c67a181e3e504c898d52"
    }
  },
  {
    "ts": null,
    "headline": "Navigating The Novo Nordisk Case With The Inversion Mental Model",
    "summary": "Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this stock may double in 5 years.",
    "url": "https://finnhub.io/api/news?id=64143f88b5434deb8778ecdecb3cf7ab3768b26445c6d6bed6cb5a8a500d4989",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755714574,
      "headline": "Navigating The Novo Nordisk Case With The Inversion Mental Model",
      "id": 136448431,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305291/image_2158305291.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this stock may double in 5 years.",
      "url": "https://finnhub.io/api/news?id=64143f88b5434deb8778ecdecb3cf7ab3768b26445c6d6bed6cb5a8a500d4989"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Viking Therapeutics Bounced Back Today",
    "summary": "Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing.",
    "url": "https://finnhub.io/api/news?id=e84f4e89aca20d838aae61131705be7a1a815e40be0acd1cf02dbc6ef7ae92d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755709156,
      "headline": "Here's Why Viking Therapeutics Bounced Back Today",
      "id": 136438660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing.",
      "url": "https://finnhub.io/api/news?id=e84f4e89aca20d838aae61131705be7a1a815e40be0acd1cf02dbc6ef7ae92d8"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Are Trading at Their Biggest Discount in 30 Years. Why a Turnaround May Have Already Started.",
    "summary": "Healthcare stocks have been in a funk.  For investors worried about elevated market valuations, they may be just what the doctor ordered.  The healthcare sector is enduring one of its worst patches on record, thanks to a slew of problems that include managed care costs and stiffening competition among blockbuster weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=bac4cf0ea7881467ff9c515fc4e6f26afbd358afa325da4a85e56015ba45cbcb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755708360,
      "headline": "Healthcare Stocks Are Trading at Their Biggest Discount in 30 Years. Why a Turnaround May Have Already Started.",
      "id": 136450253,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Healthcare stocks have been in a funk.  For investors worried about elevated market valuations, they may be just what the doctor ordered.  The healthcare sector is enduring one of its worst patches on record, thanks to a slew of problems that include managed care costs and stiffening competition among blockbuster weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=bac4cf0ea7881467ff9c515fc4e6f26afbd358afa325da4a85e56015ba45cbcb"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study",
    "summary": "VKTX shares plunge after mixed obesity pill study data shows weight loss success but high dropout rates.",
    "url": "https://finnhub.io/api/news?id=fb32903a50b2e1ac2ec92c80a8d8144412dad17f70345b8c210f5899ab76494e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755704460,
      "headline": "Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study",
      "id": 136439288,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "VKTX shares plunge after mixed obesity pill study data shows weight loss success but high dropout rates.",
      "url": "https://finnhub.io/api/news?id=fb32903a50b2e1ac2ec92c80a8d8144412dad17f70345b8c210f5899ab76494e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?",
    "summary": "AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.",
    "url": "https://finnhub.io/api/news?id=df7269fe38944b05cba71ec4287acb655269ff61fcf3a3155df8bfe7e97031b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755697200,
      "headline": "AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?",
      "id": 136437354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.",
      "url": "https://finnhub.io/api/news?id=df7269fe38944b05cba71ec4287acb655269ff61fcf3a3155df8bfe7e97031b2"
    }
  },
  {
    "ts": null,
    "headline": "Anne White to Retire as Executive Vice President and President, Lilly Neuroscience",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is underway for her successor.\"Anne's career has been defined by a deep commitment to advancing medicines for some of the most challenging diseases",
    "url": "https://finnhub.io/api/news?id=ed9f569f3262e10e70c9d7b492415aa1a395491cbf970ade9f412bda24b6127e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755694800,
      "headline": "Anne White to Retire as Executive Vice President and President, Lilly Neuroscience",
      "id": 136437355,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is underway for her successor.\"Anne's career has been defined by a deep commitment to advancing medicines for some of the most challenging diseases",
      "url": "https://finnhub.io/api/news?id=ed9f569f3262e10e70c9d7b492415aa1a395491cbf970ade9f412bda24b6127e"
    }
  },
  {
    "ts": null,
    "headline": "Lilly searching for new neuro chief as White set to retire",
    "summary": "Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly Neuroscience at the end of December.",
    "url": "https://finnhub.io/api/news?id=8f0b1c049a49bd03d73a47decff9c7b66f0575779e9c87451efdcda599868e08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755687600,
      "headline": "Lilly searching for new neuro chief as White set to retire",
      "id": 136437356,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly Neuroscience at the end of December.",
      "url": "https://finnhub.io/api/news?id=8f0b1c049a49bd03d73a47decff9c7b66f0575779e9c87451efdcda599868e08"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Neuroscience Unit President Anne White to Retire",
    "summary": "Eli Lilly Neuroscience Unit President Anne White to Retire",
    "url": "https://finnhub.io/api/news?id=ad0362e400e86d3344b2e21490fed6084d76de43ac45bc8cab3f2d4101798fe5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755681720,
      "headline": "Eli Lilly Neuroscience Unit President Anne White to Retire",
      "id": 136488135,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Neuroscience Unit President Anne White to Retire",
      "url": "https://finnhub.io/api/news?id=ad0362e400e86d3344b2e21490fed6084d76de43ac45bc8cab3f2d4101798fe5"
    }
  },
  {
    "ts": null,
    "headline": "Pharmaceuticals Industry Analysis:  Eli Lilly Tops My Tier Two",
    "summary": "Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for an analysis.",
    "url": "https://finnhub.io/api/news?id=c3907d374789a13bcc0a4f263b16cfc191ed507efec252bde9661f419a70bf5a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755663369,
      "headline": "Pharmaceuticals Industry Analysis:  Eli Lilly Tops My Tier Two",
      "id": 136435370,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291269124/image_1291269124.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for an analysis.",
      "url": "https://finnhub.io/api/news?id=c3907d374789a13bcc0a4f263b16cfc191ed507efec252bde9661f419a70bf5a"
    }
  },
  {
    "ts": null,
    "headline": "Alzheimer's Disease: When All Else Fails",
    "summary": "Most candidates fail to show meaningful clinical benefit in Alzheimer's. Read why I am against investing in companies based solely on their Alzheimer's drug programs.",
    "url": "https://finnhub.io/api/news?id=de7cc61f7b72090da27c6cd7ed9b7dc24254cb04a039676a0ff2530bb367244a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755651552,
      "headline": "Alzheimer's Disease: When All Else Fails",
      "id": 136434145,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1405486469/image_1405486469.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Most candidates fail to show meaningful clinical benefit in Alzheimer's. Read why I am against investing in companies based solely on their Alzheimer's drug programs.",
      "url": "https://finnhub.io/api/news?id=de7cc61f7b72090da27c6cd7ed9b7dc24254cb04a039676a0ff2530bb367244a"
    }
  }
]